Obesity and thyroid cancer: Is leptin the (only) link?

Endocrinology

Volumn 154, Issue 8, 2013, Pages 2567-2569

  Di Cristofano, Antonio ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; LEPTIN; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; VASCULOTROPIN;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; HUMAN; HYPERPLASIA; OBESITY; PRIORITY JOURNAL; THYROID CANCER;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; MALE; OBESITY; THYROID GLAND; THYROID NEOPLASMS;

EID: 84880661752     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1567     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Guffey CR, Fan D, Singh UP, Murphy EA. Linking obesity to colorectal cancer: Recent insights into plausible biological mechanisms. Curr Opin Clin Nutr Metab Care. In press.
3. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: A metaanalysis. Endocrine. In press.
4. Simpson ER, Brown KA. Obesity and breast cancer: A tale of inflammation and dysregulated metabolism. Mol Endocrinol. 2013; 27(5):715-725.
5. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta. In press.
6. Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women: A pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev. 2011; 20(3):464-472.
7. Almquist M, Johansen D, Björge T, et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control. 2011;22(5):743-751.
8. Rinaldi S, Lise M, Clavel-Chapelon F, et al. Body size and risk of differentiated thyroid carcinomas: Findings from the EPIC study. Int J Cancer. 2012;131(6):E1004-E1014.
9. Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, Ringel MD. The relationship between body mass index and thyroid cancer pathology features and outcomes: A clinicopathological cohort study. J Clin Endocrinol Metab. 2010;95(9):4244-4250.
10. Kim WG, Park JW, Willingham MC, Cheng S. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer via activation of the JAK2-STAT3 signaling pathway in a mouse model. Endocrinology. 2013;154:2936-2947.
11. Kim WG, Choi HJ, Kim WB, et al. Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. J Endocrinol Invest. 2012;35(4):413-418.
12. Couto JP, Daly L, Almeida A, et al. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(35): E2361-E2370.
13. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005; 65(10):4238-4245.
14. Antico Arciuch VG, Russo MA, Dima M, et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget. 2011;2(12): 1109-1126.
15. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene. 2010;29(42):5678-5686.
16. Gonzalez-Perez RR,XuY,GuoS, Watters A, ZhouW,Leibovich SJ. Leptin upregulates VEGF in breast cancer via canonic and noncanonical signalling pathways and NF-B/HIF-1α activation. Cell Signal. 2010;22(9):1350-1362.
17. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995;11(8): 1569-1579.
18. Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013;23(2):209-218.
19. Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003; 278(31):28668-28676.
20. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: An overview. J Cell Biochem. 2008;105(4):956-964.
21. Hilakivi-Clarke L, Cho E, Onojafe I. High-fat diet induces aggressive behavior in male mice and rats. Life Sci. 1996;58(19):1653-1660.
22. Clément S, Refetoff S, Robaye B, Dumont JE, Schurmans S. Low TSHrequirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology. 2001; 142(12):5131-5139.
23. Ning J, Xi G, Clemmons DR. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology. 2011;152(8):3143-3154.
24. Antico Arciuch VG, Russo MA, Kang KS, Di Cristofano A. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res. In press.